Phase II study of weekly carboplatin in pretreated adult malignant gliomas
- 24 Downloads
Patients with relapse of recurrent glioma have a poor outcome and limited treatment options. The aim of this study is to investigate the clinical benefit and tolerability of weekly intravenous administration of carboplatin-based monotherapy in adult glioma patients who had progressed from previous chemotherapy lines based on temozolomide and nitrosoureas.
This was a single-arm, phase II study. Eligibility criteria included progressive or recurrent glioma after radiotherapy and chemotherapy-based treatments and Karnofsky performance status (KPS) > 60.
Thirty-two patients (median age 43.5 years) were enrolled to receive weekly carboplatin monotherapy in an intravenous method of administration. The median duration of response was 7.3 months with an overall disease control rate of 31.3%. Median progression-free survival was 2.3 months while overall survival was 5.5 months. Pre-treatment with corticosteroids (i.e. dexamethasone) was associated to clinical benefit in 43.8% of patients. Patients achieving clinical benefit exhibited a longer progression-free survival (4.6 vs. 1.5 months; p > 0.001) and overall survival (7.9 vs. 3.2 months; p = 0.041) compared with those not achieving clinical benefit.
Our findings show that single agent, weekly, intravenous administration of carboplatin may have a role in patients with recurrent glioma and suggest that pre-treatment with corticosteroids may confer survival benefit.
KeywordsGlioblastoma Recurrence Carboplatin Progression-free survival Corticosteroid use
Editorial assistance was provided by Luca Giacomelli, PhD, Chiara Degirolamo, PhD, and Aashni Shah, from Polistudium (Milan, Italy); this assistance was supported by internal funds.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human and/or animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Regina Elena Institute, Rome, Italy) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 6.Prelaj A, Rebuzzi SE, Grassi M et al (2019) Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. Mol Clin Oncol 10:58–66Google Scholar
- 19.Prelaj A, Rebuzzi SE, Grassi M et al (2019) Multimodal treatment for local recurrent malignant gliomas: re-surgery and/or re-irradiation followed by chemotherapy. Mol Clin Oncol 10:49–57Google Scholar
- 22.Ando M, Minami H, Ando Y et al (2000) Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6:4733–4738Google Scholar